Illumina Stock

$98.20

2.93% yesterday

Nasdaq, Jul 01, 10:09 pm CET

ISIN

US4523271090

Symbol

ILMN

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Illumina Stock price

$98.15

-260.93 72.67% 5Y

Nasdaq, Closing price Tue, Jul 01 2025

+2.74 2.87%

ISIN

US4523271090

Symbol

ILMN

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$15.5b

Enterprise Value

$16.3b

Net debt

$753.0m

Cash

$1.2b

Shares outstanding

159.0m

Valuation (TTM | estimate)

P/E

negative | 22.75

P/S

3.58 | 3.60

EV/Sales

3.76 | 3.78

EV/FCF

18.60

P/B

6.59

Financial Health

Equity Ratio

37.65%

Return on Equity

-51.54%

ROCE

19.27%

ROIC

22.59%

Debt/Equity

0.84

Financials (TTM | estimate)

Revenue

$4.3b | $4.3b

EBITDA

$1.2b | $1.1b

EBIT

$914.0m

Net Income

$-965.0m | $685.9m

Free Cash Flow

$876.0m

Growth (TTM | estimate)

Revenue

-3.47% | -1.30%

EBITDA

227.73% | 70.18%

EBIT

1,675.86%

Net Income

25.14% | 156.08%

Free Cash Flow

139.34%

Margin (TTM | estimate)

Gross

66.34%

EBITDA

28.34% | 26.19%

EBIT

21.07%

Net

-22.25% | 15.90%

Free Cash Flow

20.20%

EPS

$-6.06

FCF per Share

$5.51

Short interest

6.10%

Employees

9.00k

Rev per Employee

$490.00k

As a Free StocksGuide user, you can view scores for all 6,951 stocks worldwide.

Get Started for Free Today

Illumina Stock Analysis

Unlock Scores for Free

??

30 Analysts have issued a Illumina forecast:

15x Buy

50%

13x Hold

43%

More details on Analyst Estimates Including Price Targets

30 Analysts have issued a Illumina forecast:

Buy

50%

Hold

43%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Illumina

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	4,337 4,337	3% 3% 100%
- Direct Costs	1,460 1,460	16% 16% 34%
Gross Profit	2,877 2,877	4% 4% 66%
- Selling and Administrative Expenses	889 889	40% 40% 20%
- Research and Development Expense	1,074 1,074	19% 19% 25%
EBITDA	1,229 1,229	228% 228% 28%
- Depreciation and Amortization	315 315	27% 27% 7%
EBIT (Operating Income) EBIT	914 914	1,676% 1,676% 21%
Net Profit	-965 -965	25% 25% -22%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Illumina Stock News

Positive

24/7 Wall Street

●

7 days ago

Cathie Wood Is Dumpster Diving Again With These 3 Stock Buys

Key Points in This Article: Cathie Wood's ARK Innovation ETF (ARKK) has seen a mixed performance over the past five years, reflecting her high-risk, high-reward focus on disruptive technologies to prosper over time.

Neutral

PRNewsWire

●

9 days ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO , June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive ...

Positive

24/7 Wall Street

●

12 days ago

Insiders Have Been Aggressively Buying These 5 Stocks

It's the insiders that know their company the best. And if they're willing to put their money where their mouths are, you may want to pay attention to why.

More Illumina News

Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Head office	United States
CEO	Jacob Thaysen
Employees	9,000
Founded	1998
Website	www.illumina.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now